Spero Therapeutics
SPRO
69 hedge funds and large institutions have $39.3M invested in Spero Therapeutics in 2022 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 11 increasing their positions, 20 reducing their positions, and 24 closing their positions.
153% more capital invested
Capital invested by funds: $15.5M → $39.3M (+$23.8M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7.25% less ownership
Funds ownership: 63.86% → 56.61% (-7.3%)
13% less funds holding
Funds holding: 79 → 69 (-10)
42% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 24
45% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 20
52% less call options, than puts
Call options by funds: $241K | Put options by funds: $504K
Top Buyers
| 1 |
AIC
AWM Investment Company
New York
|
+$2.29M |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$1.47M |
| 3 |
M
Murchinson
Toronto,
Ontario, Canada
|
+$758K |
| 4 |
Millennium Management
New York
|
+$372K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$201K |
Top Sellers
| 1 |
ACM
Aquilo Capital Management
San Francisco,
California
|
-$1.91M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$1.15M |
| 3 |
Renaissance Technologies
New York
|
-$720K |
| 4 |
D.E. Shaw & Co
New York
|
-$481K |
| 5 |
Two Sigma Investments
New York
|
-$324K |
SPRO Hedge Fund Activity: Q3 2022 in Review
69 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q3 2022, worth a combined $39.3M — up 153% from $15.5M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of SPRO and 14 opened new positions — a net loss of 10 holders — while 20 trimmed existing stakes and 11 added.
The largest buyer was AWM Investment Company, opening a new position worth an estimated $2.29M. The largest seller was Aquilo Capital Management, cutting an estimated $1.91M.
- 69 institutional investors held Spero Therapeutics (SPRO) as of Q3 2022, down from 79 in Q2 2022.
- Funds reported $39.3M of Spero Therapeutics stock for Q3 2022, up 153% quarter-over-quarter.
- 14 funds opened new Spero Therapeutics positions in Q3 2022 and 24 closed out, a net change of -10 holders.
- The largest Spero Therapeutics buyer in Q3 2022 was AWM Investment Company, an estimated $2.29M added.
- The largest Spero Therapeutics seller in Q3 2022 was Aquilo Capital Management, an estimated $1.91M sold.
Based on aggregated 13F filings for Q3 2022.